Peyronie's disease: AUA guideline

Ajay Nehra, Ralph Alterowitz, Daniel J. Culkin, Martha M. Faraday, Lawrence S. Hakim, Joel J. Heidelbaugh, Mohit Khera, Erin Kirkby, Kevin T. McVary, Martin M. Miner, Christian J. Nelson, Hossein Sadeghi-Nejad, Allen D. Seftel, Alan W. Shindel, Arthur Burnett

Research output: Contribution to journalArticle

Abstract

Purpose The purpose of this guideline is to provide a clinical framework for the diagnosis and treatment of Peyronie's disease. Materials and Methods A systematic review of the literature using the PubMed®, EMBASE® and Cochrane databases (search dates 1/1/1965 to 1/26/15) was conducted to identify peer-reviewed publications relevant to the diagnosis and treatment of PD. The review yielded an evidence base of 303 articles after application of inclusion/exclusion criteria. Results The systematic review was used to create guideline statements regarding treatment of PD. When sufficient evidence existed, the body of evidence for a particular treatment was assigned a strength rating of A (high quality evidence; high certainty), B (moderate quality evidence; moderate certainty), or C (low quality evidence; low certainty). Evidence-based statements of Strong, Moderate, or Conditional Recommendation were developed based on benefits and risks/burdens to patients. Additional consensus statements related to the diagnosis of PD are provided as Clinical Principles and Expert Opinions due to insufficient published evidence. Conclusions There is a continually expanding literature on PD; the Panel notes that this document constitutes a clinical strategy and is not intended to be interpreted rigidly. The most effective approach for a particular patient is best determined by the individual clinician and patient in the context of that patient's history, values, and goals for treatment. As the science relevant to PD evolves and improves, the strategies presented here will be amended to remain consistent with the highest standards of clinical care.

Original languageEnglish (US)
Pages (from-to)745-753
Number of pages9
JournalJournal of Urology
Volume194
Issue number3
DOIs
StatePublished - Sep 1 2015
Externally publishedYes

Fingerprint

Penile Induration
Guidelines
Therapeutics
Expert Testimony
Standard of Care
PubMed
Publications
Databases

Keywords

  • fibrosis
  • penile induration
  • penis

ASJC Scopus subject areas

  • Urology
  • Medicine(all)

Cite this

Nehra, A., Alterowitz, R., Culkin, D. J., Faraday, M. M., Hakim, L. S., Heidelbaugh, J. J., ... Burnett, A. (2015). Peyronie's disease: AUA guideline. Journal of Urology, 194(3), 745-753. https://doi.org/10.1016/j.juro.2015.05.098

Peyronie's disease : AUA guideline. / Nehra, Ajay; Alterowitz, Ralph; Culkin, Daniel J.; Faraday, Martha M.; Hakim, Lawrence S.; Heidelbaugh, Joel J.; Khera, Mohit; Kirkby, Erin; McVary, Kevin T.; Miner, Martin M.; Nelson, Christian J.; Sadeghi-Nejad, Hossein; Seftel, Allen D.; Shindel, Alan W.; Burnett, Arthur.

In: Journal of Urology, Vol. 194, No. 3, 01.09.2015, p. 745-753.

Research output: Contribution to journalArticle

Nehra, A, Alterowitz, R, Culkin, DJ, Faraday, MM, Hakim, LS, Heidelbaugh, JJ, Khera, M, Kirkby, E, McVary, KT, Miner, MM, Nelson, CJ, Sadeghi-Nejad, H, Seftel, AD, Shindel, AW & Burnett, A 2015, 'Peyronie's disease: AUA guideline', Journal of Urology, vol. 194, no. 3, pp. 745-753. https://doi.org/10.1016/j.juro.2015.05.098
Nehra A, Alterowitz R, Culkin DJ, Faraday MM, Hakim LS, Heidelbaugh JJ et al. Peyronie's disease: AUA guideline. Journal of Urology. 2015 Sep 1;194(3):745-753. https://doi.org/10.1016/j.juro.2015.05.098
Nehra, Ajay ; Alterowitz, Ralph ; Culkin, Daniel J. ; Faraday, Martha M. ; Hakim, Lawrence S. ; Heidelbaugh, Joel J. ; Khera, Mohit ; Kirkby, Erin ; McVary, Kevin T. ; Miner, Martin M. ; Nelson, Christian J. ; Sadeghi-Nejad, Hossein ; Seftel, Allen D. ; Shindel, Alan W. ; Burnett, Arthur. / Peyronie's disease : AUA guideline. In: Journal of Urology. 2015 ; Vol. 194, No. 3. pp. 745-753.
@article{56d21d7b7fbb415e815229c88fc848f8,
title = "Peyronie's disease: AUA guideline",
abstract = "Purpose The purpose of this guideline is to provide a clinical framework for the diagnosis and treatment of Peyronie's disease. Materials and Methods A systematic review of the literature using the PubMed{\circledR}, EMBASE{\circledR} and Cochrane databases (search dates 1/1/1965 to 1/26/15) was conducted to identify peer-reviewed publications relevant to the diagnosis and treatment of PD. The review yielded an evidence base of 303 articles after application of inclusion/exclusion criteria. Results The systematic review was used to create guideline statements regarding treatment of PD. When sufficient evidence existed, the body of evidence for a particular treatment was assigned a strength rating of A (high quality evidence; high certainty), B (moderate quality evidence; moderate certainty), or C (low quality evidence; low certainty). Evidence-based statements of Strong, Moderate, or Conditional Recommendation were developed based on benefits and risks/burdens to patients. Additional consensus statements related to the diagnosis of PD are provided as Clinical Principles and Expert Opinions due to insufficient published evidence. Conclusions There is a continually expanding literature on PD; the Panel notes that this document constitutes a clinical strategy and is not intended to be interpreted rigidly. The most effective approach for a particular patient is best determined by the individual clinician and patient in the context of that patient's history, values, and goals for treatment. As the science relevant to PD evolves and improves, the strategies presented here will be amended to remain consistent with the highest standards of clinical care.",
keywords = "fibrosis, penile induration, penis",
author = "Ajay Nehra and Ralph Alterowitz and Culkin, {Daniel J.} and Faraday, {Martha M.} and Hakim, {Lawrence S.} and Heidelbaugh, {Joel J.} and Mohit Khera and Erin Kirkby and McVary, {Kevin T.} and Miner, {Martin M.} and Nelson, {Christian J.} and Hossein Sadeghi-Nejad and Seftel, {Allen D.} and Shindel, {Alan W.} and Arthur Burnett",
year = "2015",
month = "9",
day = "1",
doi = "10.1016/j.juro.2015.05.098",
language = "English (US)",
volume = "194",
pages = "745--753",
journal = "Journal of Urology",
issn = "0022-5347",
publisher = "Elsevier Inc.",
number = "3",

}

TY - JOUR

T1 - Peyronie's disease

T2 - AUA guideline

AU - Nehra, Ajay

AU - Alterowitz, Ralph

AU - Culkin, Daniel J.

AU - Faraday, Martha M.

AU - Hakim, Lawrence S.

AU - Heidelbaugh, Joel J.

AU - Khera, Mohit

AU - Kirkby, Erin

AU - McVary, Kevin T.

AU - Miner, Martin M.

AU - Nelson, Christian J.

AU - Sadeghi-Nejad, Hossein

AU - Seftel, Allen D.

AU - Shindel, Alan W.

AU - Burnett, Arthur

PY - 2015/9/1

Y1 - 2015/9/1

N2 - Purpose The purpose of this guideline is to provide a clinical framework for the diagnosis and treatment of Peyronie's disease. Materials and Methods A systematic review of the literature using the PubMed®, EMBASE® and Cochrane databases (search dates 1/1/1965 to 1/26/15) was conducted to identify peer-reviewed publications relevant to the diagnosis and treatment of PD. The review yielded an evidence base of 303 articles after application of inclusion/exclusion criteria. Results The systematic review was used to create guideline statements regarding treatment of PD. When sufficient evidence existed, the body of evidence for a particular treatment was assigned a strength rating of A (high quality evidence; high certainty), B (moderate quality evidence; moderate certainty), or C (low quality evidence; low certainty). Evidence-based statements of Strong, Moderate, or Conditional Recommendation were developed based on benefits and risks/burdens to patients. Additional consensus statements related to the diagnosis of PD are provided as Clinical Principles and Expert Opinions due to insufficient published evidence. Conclusions There is a continually expanding literature on PD; the Panel notes that this document constitutes a clinical strategy and is not intended to be interpreted rigidly. The most effective approach for a particular patient is best determined by the individual clinician and patient in the context of that patient's history, values, and goals for treatment. As the science relevant to PD evolves and improves, the strategies presented here will be amended to remain consistent with the highest standards of clinical care.

AB - Purpose The purpose of this guideline is to provide a clinical framework for the diagnosis and treatment of Peyronie's disease. Materials and Methods A systematic review of the literature using the PubMed®, EMBASE® and Cochrane databases (search dates 1/1/1965 to 1/26/15) was conducted to identify peer-reviewed publications relevant to the diagnosis and treatment of PD. The review yielded an evidence base of 303 articles after application of inclusion/exclusion criteria. Results The systematic review was used to create guideline statements regarding treatment of PD. When sufficient evidence existed, the body of evidence for a particular treatment was assigned a strength rating of A (high quality evidence; high certainty), B (moderate quality evidence; moderate certainty), or C (low quality evidence; low certainty). Evidence-based statements of Strong, Moderate, or Conditional Recommendation were developed based on benefits and risks/burdens to patients. Additional consensus statements related to the diagnosis of PD are provided as Clinical Principles and Expert Opinions due to insufficient published evidence. Conclusions There is a continually expanding literature on PD; the Panel notes that this document constitutes a clinical strategy and is not intended to be interpreted rigidly. The most effective approach for a particular patient is best determined by the individual clinician and patient in the context of that patient's history, values, and goals for treatment. As the science relevant to PD evolves and improves, the strategies presented here will be amended to remain consistent with the highest standards of clinical care.

KW - fibrosis

KW - penile induration

KW - penis

UR - http://www.scopus.com/inward/record.url?scp=84938992195&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84938992195&partnerID=8YFLogxK

U2 - 10.1016/j.juro.2015.05.098

DO - 10.1016/j.juro.2015.05.098

M3 - Article

C2 - 26066402

AN - SCOPUS:84938992195

VL - 194

SP - 745

EP - 753

JO - Journal of Urology

JF - Journal of Urology

SN - 0022-5347

IS - 3

ER -